JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

JNJ

179.64

+1.09%↑

ABBV

220.72

+1.15%↑

UNH

344.16

-0.42%↓

NVO

55.6

-0.82%↓

AZN

73.74

+0.19%↑

Search

Eli Lilly and Co.

Затворен

СекторЗдравеопазване

724.73 1.52

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

722.59

Максимум

727.03

Ключови измерители

By Trading Economics

Приходи

2.9B

5.7B

Продажби

2.8B

16B

P/E

Средно за сектора

49.247

35.69

EPS

6.31

Дивидентна доходност

0.74

Марж на печалбата

36.384

Служители

47,000

EBITDA

3.3B

7.5B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+24.35% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

0.74%

3.08%

Следващи печалби

30.10.2025 г.

Следваща дата на дивидент

9.12.2025 г.

Следваща дата на екс-дивидент

14.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-14B

677B

Предишно отваряне

723.21

Предишно затваряне

724.73

Настроения в новините

By Acuity

26%

74%

52 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Eli Lilly and Co. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.09.2025 г., 03:10 ч. UTC

Придобивния, сливания и поглъщания

South Korea's Celltrion Plans to Invest $1 Billion to Acquire, Expand U.S. Facility

25.08.2025 г., 15:59 ч. UTC

Значими двигатели на пазара

Immuneering Shares Climb On Supply Agreement with Eli Lilly

7.08.2025 г., 11:36 ч. UTC

Печалби

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

26.09.2025 г., 13:55 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More -- Barrons.com

26.09.2025 г., 09:41 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Eli Lilly, Wayfair, Intel, Oracle, Concentrix, Costco, and More -- Barrons.com

23.09.2025 г., 02:55 ч. UTC

Придобивния, сливания и поглъщания

South Korea's Celltrion Plans to Invest $1B to Acquire, Expand U.S. Facility

23.09.2025 г., 01:27 ч. UTC

Придобивния, сливания и поглъщания

Celltrion: Investment Aims to Remove U.S. Tariff Risks

23.09.2025 г., 01:26 ч. UTC

Придобивния, сливания и поглъщания

Celltrion: To Invest Extra KRW700B to Expand Facility in Branchburg, New Jersey

23.09.2025 г., 01:26 ч. UTC

Придобивния, сливания и поглъщания

Celltrion: To Spend KRW700B for Acquisition, Initial Operating Costs

23.09.2025 г., 01:25 ч. UTC

Придобивния, сливания и поглъщания

Celltrion to Buy Biologics Facility in U.S. for $330M From Eli Lilly

22.09.2025 г., 13:43 ч. UTC

Придобивния, сливания и поглъщания

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

26.08.2025 г., 13:57 ч. UTC

Печалби

These Stocks Are Moving the Most Today: EchoStar, AT&T, AMD, Lilly, DJT, Talen Energy, Semtech, and More -- Barrons.com

26.08.2025 г., 11:37 ч. UTC

Печалби

These Stocks Are Moving the Most Today: AT&T, EchoStar, AMD, Lilly, Interactive Brokers, Talen Energy, and More -- Barrons.com

12.08.2025 г., 22:15 ч. UTC

Придобивния, сливания и поглъщания

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8.08.2025 г., 19:34 ч. UTC

Пазарно говорене

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8.08.2025 г., 05:32 ч. UTC

Пазарно говорене

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7.08.2025 г., 16:20 ч. UTC

Печалби

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7.08.2025 г., 14:18 ч. UTC

Пазарно говорене
Печалби

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7.08.2025 г., 13:54 ч. UTC

Печалби

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7.08.2025 г., 12:12 ч. UTC

Печалби

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7.08.2025 г., 11:58 ч. UTC

Печалби

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7.08.2025 г., 11:32 ч. UTC

Печалби

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7.08.2025 г., 11:03 ч. UTC

Печалби

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7.08.2025 г., 10:49 ч. UTC

Печалби

Eli Lilly 2Q Gross Margin 84.3% >LLY

7.08.2025 г., 10:48 ч. UTC

Печалби

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7.08.2025 г., 10:47 ч. UTC

Печалби

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7.08.2025 г., 10:46 ч. UTC

Печалби

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7.08.2025 г., 10:46 ч. UTC

Печалби

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7.08.2025 г., 10:46 ч. UTC

Печалби

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7.08.2025 г., 10:45 ч. UTC

Печалби

Eli Lilly 2Q Net $5.66B >LLY

Сравнение с други в отрасъла

Ценова промяна

Eli Lilly and Co. Прогноза

Ценова цел

By TipRanks

24.35% нагоре

12-месечна прогноза

Среден 900.94 USD  24.35%

Висок 1,190 USD

Нисък 700 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за Eli Lilly and Co. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

22 ratings

18

Купи

4

Задържане

0

Продай

Техническа оценка

By Trading Central

N/A / 884.54Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Strong Bearish Evidence

Настроение

By Acuity

52 / 371 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat